Kapil Mishra, MD, discusses his presentation title "Radiation Retinopathy: Future Strategies" given at the 2025 Retina World ...

As of March 31, 2025, Aura had cash and cash equivalents and marketable securities totaling $128.0 million. The Company believes its current cash and cash equivalents and marketable securities are ...

Preventing eye cancer involves a combination of health education, risk reduction, and early detection, all of which are ...

“Aura has started 2025 with strong momentum, making meaningful strides across both our ocular and urologic oncology programs,” said Elisabet de los Pinos, Ph.D., Chief Executive Officer of Aura.

Earlier this year, Cullinan said its lead candidate hit the bull's-eye in a midstage lung cancer cancer trial but stayed mum ...

Suganeswari Ganesan, head of the Ocular Oncology division at Sankara Nethralaya, emphasised the growing trend of retinoblastoma cases not only in India but also in countries like Bangladesh ...

Data to be presented at ASCO reflect Boehringer's broad pipeline and growing body of evidence supporting innovative therapies for various cancersPatient-reported outcomes from the Beamion LUNG-1 study ...

Bristol-Myers Squibb (NYSE:BMY) is advancing in oncology, as evidenced by its upcoming presentations at the 2025 ASCO Annual ...

Dr Louisa Dlamini from Mabopane makes history as the University of Pretoria’s first black graduate with an MMed in Radiation ...

Discover "Bevacizumab - Biosimilar Insight, 2025," which analyzes 25+ companies and 30+ drugs in the bevacizumab biosimilars landscape. The report covers marketed drugs, pipeline molecules, and ...

All of the shares, pre-funded warrants and accompanying common stock warrants in the offering are being sold by Aura. The gross proceeds from the offering to Aura are expected to be $75.0 million, ...

Genmab has shared the first data on rinatabart sesutecan (Rina-S) in advanced endome | Genmab has shared the first data on ...